Literature DB >> 9649014

Abnormal liver test results in myotonic dystrophy.

A Achiron1, Y Barak, N Magal, M Shohat, M Cohen, R Barar, N Gadoth.   

Abstract

Myotonic dystrophy (DM) is an autosomal dominant multisystem disorder. Little evidence suggests the existence of liver damage in a small number of patients. We have prospectively evaluated liver and gallbladder function in 53 patients with DM in relation to clinical and genetic parameters. None of the patients had an enlarged liver, signs of cirrhosis, or portal hypertension. All were free of medication, and none were pregnant or had a history of alcohol abuse. In 35 (66%) patients, serum activity of at least one of six liver enzymes assayed was abnormal. An elevated level of alkaline phosphatase was found in 50.9%, of gamma-glutamyltransferase in 52.8%, of 5' nucleotidase in 43.4%, of serum aspartate aminotransferase in 35.8%, of serum alanine aminotransferase in 33.9%, and of lactate dehydrogenase in 37.7%. Liver function test results did not correlate with severity of muscle weakness, disease duration, or serum levels of creatine kinase, glucose, or lipids. Motility of gallbladder and abdominal ultrasonography were normal. Cytosine-thymidine-guanine repeat expansion by southern blot did not correlate with liver enzyme abnormalities. We conclude that elevation of liver enzymes is frequent in DM and should be included as an additional laboratory finding of the disease.

Entities:  

Mesh:

Year:  1998        PMID: 9649014     DOI: 10.1097/00004836-199806000-00016

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  9 in total

1.  Elevated liver enzymes indicating a diagnosis of limb-girdle muscular dystrophy.

Authors:  Tyler Lash; Ryan R Kraemer
Journal:  J Gen Intern Med       Date:  2014-01-23       Impact factor: 5.128

Review 2.  The role of CUGBP1 in age-dependent changes of liver functions.

Authors:  Karlie Jones; Lubov Timchenko; Nikolai A Timchenko
Journal:  Ageing Res Rev       Date:  2012-03-14       Impact factor: 10.895

Review 3.  Myotonic dystrophy.

Authors:  Charles A Thornton
Journal:  Neurol Clin       Date:  2014-06-06       Impact factor: 3.806

4.  Intrinsically cell-penetrating multivalent and multitargeting ligands for myotonic dystrophy type 1.

Authors:  JuYeon Lee; Yugang Bai; Ullas V Chembazhi; Shaohong Peng; Kevin Yum; Long M Luu; Lauren D Hagler; Julio F Serrano; H Y Edwin Chan; Auinash Kalsotra; Steven C Zimmerman
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-11       Impact factor: 11.205

5.  [Upper abdominal pain, nausea, and vomiting in a 63-year-old woman].

Authors:  S Schwarzer; K Rapis
Journal:  Internist (Berl)       Date:  2017-12       Impact factor: 0.743

6.  Non-Alcoholic Steatohepatitis in Myotonic Dystrophy: DMPK Gene Mutation, Insulin Resistance and Development of Steatohepatitis.

Authors:  Rishi R Bhardwaj; Andrea Duchini
Journal:  Case Rep Gastroenterol       Date:  2010-03-17

7.  Hormonal and metabolic gender differences in a cohort of myotonic dystrophy type 1 subjects: a retrospective, case-control study.

Authors:  M Spaziani; A Semeraro; E Bucci; F Rossi; M Garibaldi; M A Papassifachis; C Pozza; A Anzuini; A Lenzi; G Antonini; A F Radicioni
Journal:  J Endocrinol Invest       Date:  2019-11-30       Impact factor: 4.256

8.  High Prevalence and Gender-Related Differences of Gastrointestinal Manifestations in a Cohort of DM1 Patients: A Perspective, Cross-Sectional Study.

Authors:  Alessia Perna; Daria Maccora; Salvatore Rossi; Tommaso Filippo Nicoletti; Maria Assunta Zocco; Vittorio Riso; Anna Modoni; Antonio Petrucci; Venanzio Valenza; Antonio Grieco; Luca Miele; Gabriella Silvestri
Journal:  Front Neurol       Date:  2020-06-12       Impact factor: 4.003

Review 9.  Muscle wasting in myotonic dystrophies: a model of premature aging.

Authors:  Alba Judith Mateos-Aierdi; Maria Goicoechea; Ana Aiastui; Roberto Fernández-Torrón; Mikel Garcia-Puga; Ander Matheu; Adolfo López de Munain
Journal:  Front Aging Neurosci       Date:  2015-07-09       Impact factor: 5.750

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.